Caffeine Contracture of the Skinned Muscle Fiber in Malignant Hyperthermia and Neuromuscular Diseases

  • Akio Takagi
  • Makoto Araki
  • Susumu Kojima
  • Masayoshi Ida
  • Tomoji Watanabe
Conference paper


Caffeine contracture of skinned muscle fiber was analyzed in subjects who had recovered from malignant hyperthermia (MH) and in patients with other neuromuscular diseases. In several muscle specimens, the calcium-induced (Ca-induced) Ca release (CICR) was also studied and compared to the caffeine contracture. The caffeine contracture test was very sensitive in detecting abnormalities, but it seemed less specific for diagnosis of true MH.


Duchenne Muscular Dystrophy Spinal Muscular Atrophy Neuroleptic Malignant Syndrome Neuromuscular Disease Duchenne Muscular Dystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Morio M, Kikuchi H, Yuge O, et al (1988) Clinical criteria of malignant hyperthermia. Revised criteria. In: Proceedings of the 11th Japanese symposium of malignant hyperthermia, 1988, pp 104–110Google Scholar
  2. 2.
    Takagi A, Sunohara N, Ishihara T, et al (1983) Malignant hyperthermia and related neuromuscular diseases: caffeine contracture of the skinned fibers. Muscle Nerve 6: 510–514PubMedCrossRefGoogle Scholar
  3. 3.
    Takagi A, Yonemoto K, Sugita H (1978) Single human muscle fibers: activation by calcium and strontium. Neurology 28: 497–499PubMedGoogle Scholar
  4. 4.
    Endo M, Yagi S, Ishizuka Y, et al (1983) Changes in the Ca-induced Ca release of the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomed Res 4: 83–92Google Scholar
  5. 5.
    Kalow W, Britt BA, Terreau ME, et al (1970) Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 2: 895–898PubMedCrossRefGoogle Scholar
  6. 6.
    Takagi A, Sugita H, Toyokura Y, Endo M (1976) Malignant hyperpyrexia. Effect of halothane on single skinned muscle fibers. Proc Jpn Acad 52: 603–606Google Scholar
  7. 7.
    Otsuka H, Komura Y, Mayumi T, et al (1991) Malignant hyperthermia during sevoflurane anesthesia in a child with central core disease. Anesthesiology 75: 699–701PubMedCrossRefGoogle Scholar
  8. 8.
    Lai FA, Erickson HP, Rousseau E, et al (1988) Purification and reconstitution of the calcium release channel from skeletal muscle. Nature 331: 315–319PubMedCrossRefGoogle Scholar
  9. 9.
    Gillard EF, Otsu K, Fujii J, et al (1992) Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor gene in individuals with malignant hyperthermia. Genomics 13: 1247–1254PubMedCrossRefGoogle Scholar
  10. 10.
    Quane KA, Healy JMS, Keating KE, et al (1993) Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genet 5: 51–55PubMedCrossRefGoogle Scholar
  11. 11.
    Kawana Y, Iino M, Horiuti K, et al (1992) Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia. Biomed Res 13: 287–297Google Scholar
  12. 12.
    Heytens L, Martin JJ, Van De Kelft E, Bossaert LL (1992) In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth 68: 72–75PubMedCrossRefGoogle Scholar
  13. 13.
    Heimann-Patterson TD, Natter HM, Rosenberg HR, et al (1986) Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatr Neurol 2: 356–358CrossRefGoogle Scholar
  14. 14.
    Sethna NF, Rockoff MA, Worthen M, Rosnow JM (1988) Anesthesia-related complications in children with Duchenne muscular dystrophy. Anesthesiology 68: 462–465PubMedCrossRefGoogle Scholar
  15. 15.
    Larsen UT, Juhl B, Hein-Sorensen O, Olivarius BDF (1989) Complications during anaesthesia in patients with Duchenne’s muscular dystrophy (a retrospective study). Can J Anaesth 36: 418–22PubMedCrossRefGoogle Scholar
  16. 16.
    Gronert GA, Fowler W, Cardinet GH, et al (1992) Absence of malignant hyperthermia contractures in Becker-Duchenne dystrophy at age 2. Muscle Nerve 15: 52–56PubMedCrossRefGoogle Scholar
  17. 17.
    Salviati G, Betto R, Ceoldo S, et al (1989) Caffeine sensitivity of sarcoplasmic reticulum of fast and slow fibers from normal and malignant hyperthermia human muscle. Muscle Nerve 12: 365–370PubMedCrossRefGoogle Scholar
  18. 18.
    Dangain J, Neering I (1993) Effect of caffeine and high potassium on normal and dystrophic mouse EDL muscles at various developmental stages. Muscle Nerve 16: 3342CrossRefGoogle Scholar
  19. 19.
    Geiduschek J, Cohen SA, Khan A, et al (1988) Repeated anesthesia for a patient with neuroleptic malignant syndrome. Anesthesiology 68: 134–137PubMedCrossRefGoogle Scholar
  20. 20.
    Takagi A, Kojima S, Ida M, Araki M (1992) Increased leakage of calcium ion from the sarcoplasmic reticulum of the mdx mouse. J Neurol Sci 110: 160–164PubMedCrossRefGoogle Scholar
  21. 21.
    Takagi A, Kojima S, Araki M, et al (1989) Clinical implications of enhanced caffeine contracture in malignant hyperthermia and Duchenne muscular dystrophy (in Japanese). Clin Neurol (Tokyo) 29: 301–305Google Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Akio Takagi
    • 1
  • Makoto Araki
    • 1
  • Susumu Kojima
    • 1
  • Masayoshi Ida
    • 1
  • Tomoji Watanabe
    • 1
  1. 1.Department of NeurologyToranomon Hospital and Okinaka Memorial Institute for Medical ResearchMinato-ku, Tokyo, 105Japan

Personalised recommendations